How much funding has SHANTON raised?

SHANTON has raised $31.2M in total funding, most recently a Series A round.

What industry is SHANTON in?

SHANTON operates in Biotech, Healthcare.

SHANTON

Q: Who are SHANTON's investors?

SHANTON's investors include BioTrack Capital, Cenova Capital, Lapam Capital.

Developing novel treatments for gout, hyperuricemia, and pruritus

Founded 2016 · $31.2M raised

Biotech

Healthcare

Founded: 2016
Website: shantonpharma.com
Total Funding: $31.2M

Last Round: $31.2M Series ADec 2020
Rounds: 1

About

Shanton Pharma is a clinical-stage biotech company founded in 2016, focused on the unmet needs associated with gout, hyperuricemia, and pruritus. The company's mission is to develop novel treatments that address global clinical gaps in these inflammatory and metabolic disease areas, with an ultimate goal of completely eliminating gout. Shanton's pipeline includes SAP-001, which has received FDA Fast Track Designation for refractory gout and has completed an End-of-Phase 2 meeting with the US FDA. The company brings together experienced management with relevant drug development track records and is backed by a group of institutional investors focused on biotech.

Summary

SHANTON is a Biotech company, founded in 2016. It has raised $31.2M in total across 1 round, most recently a $31.2M Series A round in Dec 2020. Investors include BioTrack Capital, Cenova Capital and Lapam Capital.